Line 1,692: |
Line 1,692: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |Diffuse large B-cell lymphoma, NOS||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center |
Line 1,699: |
Line 1,699: |
| | | | | |
| |- | | |- |
− | |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,706: |
Line 1,706: |
| | | | | |
| |- | | |- |
− | |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland |
Line 1,713: |
Line 1,713: |
| | | | | |
| |- | | |- |
− | |ALK-positive large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) |
Line 1,720: |
Line 1,720: |
| | | | | |
| |- | | |- |
− | |Large B-cell lymphoma with IRF4 rearrangement||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |*Afia Hasnain, MBBS, PhD | | |*Afia Hasnain, MBBS, PhD |
Line 1,727: |
Line 1,727: |
| | | | | |
| |- | | |- |
− | |High grade B-cell lymphoma with 11q aberrations||Disease|| || || || || ||GC|| || | + | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina |
Line 1,734: |
Line 1,734: |
| | | | | |
| |- | | |- |
− | |Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,741: |
Line 1,741: |
| | | | | |
| |- | | |- |
− | |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,748: |
Line 1,748: |
| | | | | |
| |- | | |- |
− | |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,755: |
Line 1,755: |
| | | | | |
| |- | | |- |
− | |Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,762: |
Line 1,762: |
| | | | | |
| |- | | |- |
− | |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| | | | | |
Line 1,769: |
Line 1,769: |
| | | | | |
| |- | | |- |
− | |Plasmablastic lymphoma||Disease|| || || || || ||GC|| || | + | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| || |
| | | | | |
| |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |